ReviewInternational journal of nanomedicine2026
Research Progress and Preclinical Prospects of Plant-Derived Extracellular Vesicles in Targeted Delivery of Antitumor Drugs.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived extracellular vesicles (PDEVs) have emerged as a novel class of bionanocarriers, garnering significant attention in the targeted delivery of antitumor drugs due to their low immunogenicity, excellent biocompatibility, and intrinsic antitumor properties. This review provides a comprehensive overview of the biological characteristics and extraction methods of PDEVs, emphasizing their recent advances in the field of antitumor drug delivery. We critically analyze the mechanisms by which PDEVs derived from various plants modulate the tumor microenvironment, enhance drug targeting specificity, and stimulate antitumor immunity. Furthermore, we discuss the advantages and current challenges faced by PDEVs as drug delivery vectors, including standardization, reproducibility, in vivo targeting evidence. The review also explores the promising potential of PDEVs in precision oncology, highlighting their role in improving therapeutic outcomes and minimizing off-target effects. This review aims to provide theoretical insights for the development and clinical application of PDVEs in the targeted delivery of anti-tumor drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.